Open AccessHIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era
Author(s) -
Maria Joao Baptista,
Olga García,
Mireia Morgades,
Eva González Barca,
Pilar Miralles,
Armando LópezGuillermo,
Eugènia Abella,
Miriam Moreno,
JuanManuel Sancho,
Evarist Feliú,
JosepMaría Ribera,
José-Tomás Navarro
Publication year - 2015
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000624
Subject(s) - medicine , diffuse large b cell lymphoma , rituximab , vincristine , lymphoma , chop , immunosuppression , prednisone , cyclophosphamide , oncology , chemotherapy
Since the introduction of combination antiretroviral therapy (cART) patients with HIV-related diffuse large B-cell lymphoma (DLBCL) show better control of immunosuppression, which may have an impact on the characteristics and prognosis of the disease. We aimed to compare the clinical presentation and prognosis of patients with HIV-related and HIV-unrelated DLBCL treated with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) in the cART era.